Abstract
In recent years molecular cloning studies have resulted in the discovery of multiple genes encoding a variety of structural and functional subunits for nicotinic cholinergic receptors (nAChR) (Galzi and Changeux, 1995), 11 having neuronal localization (α2–α9, β2–β4) and 5 expressed in skeletal muscle (α1, β1,γ, δ, ε). This molecular diversity opens up the possibility of complex receptor subtype expression both in the autonomic (PNS) and central (CNS) nervous systems, possibly explaining the complex pharmacological effects of nicotine and other classic nicotinic cholinergic agonists that do not discriminate among the various receptor subtypes expressed in the CNS and PNS. The importance of understanding this complexity is emphasized by the growing body of evidence suggesting that compromised CNS nicotinic cholinergic neurotransmission may play a key role in a variety of CNS and PNS pathologies. In this regard, there is growing interest in the use of nicotinic agonists for the treatment of Alzheimer’s disease (AD) (Williams et al., 1994). One consistent feature of this disease is a decline in the function of cholinergic systems. The loss of neurons that release acetylcholine, a key neurotransmitter in learning and memory mechanisms, initially motivated an intense but disappointing search for replacement therapies targeting muscarinic receptors. On the other hand, epidemiological studies have reported an inverse correlation between the incidence of AD and smoking (van Duijn and Hofman, 1991), supporting the notion that nicotinic pharmacology underlies an apparent protective effect.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bencherif M, Fowler K, Lukas RJ and Lippiello PM (1995a): Mechanisms of up-regulation of neuronal nicotinic acetylcholine receptors in clonal cell lines and primary cultures of fetal rat brain. J Pharmacol Exp Ther 275: 987–994.
Bencherif M, Lovette ME, Arrington S, Fowler K, Reeves L, Caldwell WS and Lippiello PM (1995b): Metanicotine: a nicotinic agonist with CNS selectivity-in vitro characterization. Abst Soc Neurosci 21: 605.
Galzi JL and Changeux JP (1995): Neuronal nicotinic receptors; Molecular organization and regulations. Neuropharmacology 34: 563–582.
Grady SR, Marks MJ, Wonnacott S and Collins AC (1992): Characterization of nicotinic receptor-mediated [3H]-dopamine release from synaptosomes prepared from mouse striatum. J Neurochem 59: 848–856.
Hodges H, Allen Y, Sinden J, Lantos PL and Gray JA (1991): Effects of cholinergic-rich neural grafts on radial maze performance of rats after excitotoxic lesions of the forebrain projection system-II. Cholinergic drugs as probes to investigate lesion-induced deficits and transplant-induced functional recovery. Neuroscience 45: 609–623.
Lippiello PM and Fernandes KG (1986): The binding of L-[3H] nicotine to a single class of high affinity sites in rat brain membranes. Mol Pharmacol 29: 448–454.
Lippiello PM, Gray JA, Peters S, Grigoryan G, Hodges H, Summers K, Giacobini E and Collins AC (1995): Metanicotine: A nicotinic agonist with CNS selectivity-in vivo characterization. Abst Soc Neurosci 21: 605.
Lukas RJ (1991): Effects of chronic nicotinic ligand exposure on functional activity of nicotinic acetylcholine receptors expressed by cells of the PC 12 rat pheochromocytoma or the TE671/RD human clonal lines. J Neurochem 56: 1134–1145.
Marks MJ and Collins AC (1982): Characterization of nicotine binding in mouse brain and comparison with the binding of α-bungarotoxin and quinuclidinyl benzilate. Mol Pharmacol 22: 554–564.
Marks MJ, Romm E, Bealer S, and Collins AC (1985): A test battery for measuring nicotine effects in mice. Pharmacol Biochem Behav 23:325–330.
Marks MJ, Farnham DA, Grady SR and Collins AC (1993): Nicotinic receptor function determined by stimulation of rubidium efflux from mouse brain synaptosomes. J Pharmacol Exp Ther 264: 542–552.
Reavill C, Walther B, Stolerman, IP and Testa B (1990): Behavioral and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacol. 29: (619–624).
Sahakian B, Jones G, Levy R, Gray JA and Warburton D (1989): The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry 154:797–800.
Summers KL, Lippiello PM, Verhulst S and Giacobini E (1995): 5-Fluoronicotine, noranhydroecgonine and pyridyl-methylpyrrolidine release acetylcholine and biogenic amines in rat cortex in vivo. Neurochem Res 20: 1089–1094.
van Duijn CM and Hofman A (1991): Relation between nicotine intake and Alzheimer’s disease. Brit Med J 302: 1491–1494.
Williams M, Sullivan JP and Arneric SP (1994): Neuronal nicotinic acetylcholine receptors. Drug News & Perspectives 7: 205–223.
Wilson AL, Langley LK, Monley J, Bauer T, Rottunda S, Malls E, Kovera C and Marten JR (1995): Nicotine patches in Alzheimer’s disease:pilot study on learning, memory, and safety. Pharmacol Biochem Behav 51:509–514.
Wonnacott S, Drasdo A, Sanderson E, and Rowell P (1990): Presynaptic nicotinic receptors and the modulation of transmitter release. In The Biology of Nicotine Dependence. Bock G and Marsh J, eds., John Wiley & Sons, Chichester, pp. 87–101.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Birkhäuser Boston
About this chapter
Cite this chapter
Lippiello, P.M. et al. (1997). RJR-2403: A CNS-Selective Nicotinic Agonist with Therapeutic Potential. In: Becker, R.E., Giacobini, E., Barton, J.M., Brown, M. (eds) Alzheimer Disease. Advances in Alzheimer Disease Therapy. Birkhäuser Boston. https://doi.org/10.1007/978-1-4612-4116-4_41
Download citation
DOI: https://doi.org/10.1007/978-1-4612-4116-4_41
Publisher Name: Birkhäuser Boston
Print ISBN: 978-1-4612-8660-8
Online ISBN: 978-1-4612-4116-4
eBook Packages: Springer Book Archive